BridgeBio Pharma Other Current Liabilities

BridgeBio Pharma (BBIO) currently reports a other current liabilities of $750M as of March 2026. That compares with $110M in the prior-year period — up 596.8% year over year. Use the charts on this page to explore BridgeBio Pharma's other current liabilities history and peer comparisons.

BridgeBio Pharma's other current liabilities increased from $110M to $750M — a 596.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BridgeBio Pharma reported $750M in other current liabilities as of March 2026. That compares with $110M in the prior-year period — up 596.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $750M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BridgeBio Pharma, and consider following BBIO for alerts when major investors trade the stock.

BridgeBio Pharma is classified in the Healthcare sector. On other current liabilities, it currently shows $750M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BBIO with unrelated industries.